{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:36:30Z","timestamp":1787841390105,"version":"build-2784847793"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>\n                      This study aimed to perform dosimetry in patients with metastatic prostate cancer treated with\n                      <jats:sup>177<\/jats:sup>\n                      Lutetium (Lu) prostate-specific membrane antigen (PSMA)-617 radiopharmaceutical, calculating organ blood clearance and consequently determining the maximum tolerable treatment activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Eighteen patients with metastatic prostate cancer were enrolled in the study. Patients were administered 5.55 gigabecquerel (GBq) of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617 radiopharmaceutical per treatment cycle through infusion. Blood samples (2 mL each) were collected at 2, 4, 6, 8, 18, 24, 36, and 44 h postinjection to assess the bone marrow absorbed dose. Organ doses were calculated using the OLINDA\/EXM software based on scintigraphic images of the 18 patients who received\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The blood clearance of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617 radiopharmaceutical was determined to be bi-exponential. The mean absorbed doses for the parotid glands, kidneys, bone marrow, and liver were found to be 1.18 \u00b1 0.27, 1.05 \u00b1 0.3, 0.07 \u00b1 0.05, and 0.31 \u00b1 0.2 Gy\/GBq, respectively. The radiation dose to the bone marrow was significantly lower than that to the kidneys and parotid glands. No dose limitations were necessary for kidneys and bone marrow in any of the patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Our dosimetry results indicate that\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617 therapy is safe in terms of radiation toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jmp.jmp_12_24","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T09:27:14Z","timestamp":1719912434000},"page":"304-310","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Determination of Critical Organ Doses with 177Lu Prostate-specific Membrane Antigen Dosimetry in Metastatic Prostate Cancer Treatment"],"prefix":"10.4103","volume":"49","author":[{"given":"Gulcihan","family":"Yilidir","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"R1-20240906","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R2-20240906","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","article-title":"(177) Lu-PSMA radioligand therapy for prostate cancer","volume":"58","author":"Fendler","year":"2017","journal-title":"J Nucl Med"},{"key":"R3-20240906","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","article-title":"Asystematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer","volume":"80","author":"Sadaghiani","year":"2021","journal-title":"Eur Urol"},{"key":"R4-20240906","first-page":"P398","article-title":"Radionuclide therapy applications in the treatment of prostate cancer","volume":"10","author":"Akyel","year":"2017","journal-title":"Turk Clin J Med Oncol Spec Top"},{"key":"R5-20240906","first-page":"P123","article-title":"Tolerance of normal tissue to therapeutic radiation","volume":"1","author":"Emami","year":"2013","journal-title":"Rep Radiother Oncol"},{"key":"R6-20240906","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1073\/pnas.93.2.749","article-title":"Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase","volume":"93","author":"Carter","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R7-20240906","first-page":"3192","article-title":"Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","author":"Chang","year":"1999","journal-title":"Cancer Res"},{"key":"R8-20240906","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RLU.0000000000002833","article-title":"Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"45","author":"Yadav","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R9-20240906","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2967\/jnumed.115.158550","article-title":"68Ga- and 177Lu-Labeled PSMA I and T:Optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies","volume":"56","author":"Weineisen","year":"2015","journal-title":"J Nucl Med"},{"key":"R10-20240906","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2967\/jnumed.116.178483","article-title":"Radiation dosimetry for (177)Lu-PSMA I and T in metastatic castration-resistant prostate cancer:Absorbed dose in normal organs and tumor lesions","volume":"58","author":"Okamoto","year":"2017","journal-title":"J Nucl Med"},{"key":"R11-20240906","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2967\/jnumed.118.222307","article-title":"First clinicopathologic evidence of a Non-PSMA-related uptake mechanism for (68)Ga-PSMA-11 in salivary glands","volume":"60","author":"Rupp","year":"2019","journal-title":"J Nucl Med"},{"key":"R12-20240906","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4274\/mirt.08760","article-title":"Lu-177-PSMA-617 prostate-specific membrane antigen \u0131nhibitor therapy in patients with castration-resistant prostate cancer:Stability, bio-distribution and dosimetry","volume":"26","author":"Kabasakal","year":"2017","journal-title":"Mol Imaging Radionucl Ther"},{"key":"R13-20240906","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","article-title":"Prostate-specific membrane antigen expression as a predictor of prostate cancer progression","volume":"38","author":"Perner","year":"2007","journal-title":"Hum Pathol"},{"key":"R14-20240906","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","article-title":"Pre-therapeutic dosimetry of normal organs and tissues of (177) Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer","volume":"42","author":"Kabasakal","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-20240906","first-page":"1725","article-title":"Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy:A multiinstitutional comparison","volume":"45","author":"Wessels","year":"2004","journal-title":"J Nucl Med"},{"key":"R16-20240906","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","article-title":"EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry","volume":"37","author":"Hindorf","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R17-20240906","first-page":"37S","article-title":"MIRD pamphlet no. 16:Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates","volume":"40","author":"Siegel","year":"1999","journal-title":"J Nucl Med"},{"key":"R18-20240906","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2967\/jnumed.108.053173","article-title":"MIRD pamphlet No. 20:The effect of model assumptions on kidney dosimetry and response \u2013\u0130mplications for radionuclide therapy","volume":"49","author":"Wessels","year":"2008","journal-title":"J Nucl Med"},{"key":"R19-20240906","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","article-title":"Dosimetry for (177)Lu-DKFZ-PSMA-617:A new radiopharmaceutical for the treatment of metastatic prostate cancer","volume":"43","author":"Delker","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R20-20240906","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11307-016-0942-0","article-title":"Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [(177)Lu] DKFZ-PSMA-617","volume":"18","author":"Hohberg","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"R21-20240906","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer:Correlations between pretherapeutic \u0131maging and whole-body tumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J Nucl Med"},{"key":"R22-20240906","first-page":"292","article-title":"Examining absorbed doses of \u0131ndigenously developed (177) Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients at baseline and during course of peptide receptor radioligand therapy","volume":"36","author":"Kamaldeep","year":"2021","journal-title":"Cancer Biother Radiopharm"},{"key":"R23-20240906","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00259-020-05022-3","article-title":"Biodistribution and dosimetry of a single dose of albumin-binding ligand [(177)Lu] Lu-PSMA-ALB-56 in patients with mCRPC","volume":"48","author":"Kramer","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R24-20240906","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.2967\/jnumed.115.170720","article-title":"The rise of PSMA ligands for diagnosis and therapy of prostate cancer","volume":"57","author":"Afshar-Oromieh","year":"2016","journal-title":"J Nucl Med"},{"key":"R25-20240906","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00259-016-3419-0","article-title":"Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing","volume":"43","author":"Afshar-Oromieh","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R26-20240906","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00259-010-1549-3","article-title":"EANM dosimetry committee guidance document:Good practice of clinical dosimetry reporting","volume":"38","author":"Lassmann","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R27-20240906","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1530\/ERC-16-0524","article-title":"Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [(177)Lu-DOTA(0), Tyr(3)]octreotate","volume":"24","author":"Brabander","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"R28-20240906","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41375-019-0677-4","article-title":"The therapeutic effectiveness of (177)Lu-lilotomab in B-cell non-hodgkin lymphoma involves modulation of G2\/M cell cycle arrest","volume":"34","author":"Pichard","year":"2020","journal-title":"Leukemia"},{"key":"R29-20240906","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","article-title":"Radiation-associated liver injury","volume":"76","author":"Pan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R30-20240906","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2967\/jnumed.118.223149","article-title":"(177)Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney","volume":"60","author":"Zhang","year":"2019","journal-title":"J Nucl Med"},{"key":"R31-20240906","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2967\/jnumed.119.226449","article-title":"Effect of external cooling on (177)Lu-PSMA uptake by the parotid glands","volume":"60","author":"Yilmaz","year":"2019","journal-title":"J Nucl Med"},{"key":"R32-20240906","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2967\/jnumed.112.107524","article-title":"Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment","volume":"54","author":"Sandstr\u00f6m","year":"2013","journal-title":"J Nucl Med"},{"key":"R33-20240906","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2967\/jnumed.118.225235","article-title":"Bone marrow absorbed doses and correlations with hematologic response during (177)Lu-DOTATATE treatments are \u0131nfluenced by \u0131mage-based dosimetry method and presence of skeletal metastases","volume":"60","author":"Hagmarker","year":"2019","journal-title":"J Nucl Med"}],"container-title":["Journal of Medical Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jmp.jmp_12_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:52:29Z","timestamp":1787838749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jmp.jmp_12_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jmp.jmp_12_24","relation":{},"ISSN":["0971-6203","1998-3913"],"issn-type":[{"value":"0971-6203","type":"print"},{"value":"1998-3913","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"2024-01-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}